The Journal of Huntington's Disease published the finding of Kevin M. Biglan, MD, and his colleagues of a possibility for coenzyme Q10 (CoQ10) to retard the progression of Huntington's disease.*
CoQ10, due to its support of the cells' mitochondria and its antioxidant effect, has been investigated as a possible agent to treat Huntington's disease. The current research evaluated 20 Huntington's disease patients and 8 controls that had been given CoQ10 in a clinical trial. Blood samples obtained at the beginning and end of treatment were analyzed for serum 80HdG, which has been correlated with oxidative stress in the brain's cells and has been found to be elevated in those with Huntington's disease.
While the trial had found a reduction in Huntington's disease symptoms after treatment with CoQ10, the current research uncovered a 17% reduction in 8OHdG levels in Huntington's disease patients as well as a nonsignificant reduction in subjects who did not have the disease.
Editor's Note: Huntington's disease is a neurodegenerative disorder caused by a genetic error that produces abnormal proteins in the brain's cells. Scientists believe that these protein deposits result in oxidative stress that ultimately kills the cells that contain them. "This study supports the hypothesis that CoQ10 exerts antioxidant effects in patients with Huntington's disease and therefore is a treatment that warrants further study," Dr. Biglan concluded.